53. Sjogren syndrome
[
130 clinical trials,
158 drugs（DrugBank:
64 drugs),
45 target genes / 170 target pathways ]
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03953703 | December 1, 2019 | 9 September 2019 | Levocarnitine for Dry Eye in Sjogren's Syndrome | A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Levocarnitine for the Treatment of Keratoconjunctivitis Sicca in Sjogren's Syndrome | Sjogren's Syndrome;Keratoconjunctivitis Sicca | Drug: Levocarnitine;Drug: Placebo | Vanderbilt University Medical Center | Not recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | ||
| 2 | NCT04093531 | November 2019 | 4 November 2019 | Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome | Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome | Primary Sjögren Syndrome | Drug: Ustekinumab | University of Rochester | Not recruiting | 18 Years | 75 Years | All | 15 | Phase 1 | ||
| 3 | NCT04129164 | October 23, 2019 | 4 November 2019 | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS) | Sjögren's Syndrome | Drug: VIB4920;Drug: Placebo | Viela Bio | Not recruiting | 18 Years | 75 Years | All | 174 | Phase 2 | ||
| 4 | NCT03905525 | October 1, 2019 | 4 November 2019 | Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome | A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren's Syndrome (TWINSS) | Sjögren Syndrome | Drug: CFZ533;Other: Placebo | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 260 | Phase 2 | Australia;Hungary;Japan;Turkey | |
| 5 | NCT03841318 | September 2019 | 26 August 2019 | Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome | Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome | Sjogren's Syndrome | Biological: blood sample;Biological: biopsy of the labial salivary gland | University Hospital, Bordeaux | Not recruiting | 18 Years | N/A | All | 200 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | ChiCTR1900024642 | 2019-08-01 | 22 July 2019 | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Experimental group:Iguratimod+Prednisone;control group:HCQ+Prednisone; | Chongqing Hospital of Traditional Chinese Medcine | Recruiting | 18 | 65 | Both | Experimental group:30;control group:30; | N/A | China | |
| 7 | NCT04035668 | July 12, 2019 | 11 November 2019 | A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome | An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) | Sjögren Syndrome | Drug: LOU064;Drug: Placebo | Novartis Pharmaceuticals | Recruiting | 18 Years | 75 Years | All | 252 | Phase 2 | Australia;Germany;Hungary;Spain;Switzerland | |
| 8 | NCT04078386 | June 28, 2019 | 16 September 2019 | A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome | A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg | RemeGen | Recruiting | 18 Years | 65 Years | All | 30 | Phase 2 | China | |
| 9 | NCT03700138 | June 24, 2019 | 2 September 2019 | Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies | Prospective, Randomised, Placebo-controlled Study of Polyvalent Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies | Primary Sjögren's Syndrome Painful Sensory Neuropathies | Drug: Privigen® 100mg/ml at the dose of 2g/kg of body weight;Drug: NaCl 0,9% | University Hospital, Strasbourg, France | Recruiting | 18 Years | 80 Years | All | 24 | Phase 3 | France | |
| 10 | NCT03983408 | June 17, 2019 | 24 June 2019 | Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease | Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease | Sjögren's Syndrome;Rheumatic Diseases;Korean Red Ginseng | Dietary Supplement: Korean Red ginseng;Dietary Supplement: Placebo | Hanyang University | The Korean Society of Ginseng | Not recruiting | 19 Years | 75 Years | All | 120 | N/A | Korea, Republic of |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | ChiCTR1900022696 | 2019-06-01 | 30 April 2019 | A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome | A prospective, controlled, randomized, open-label, single-center study for eramyd in the treatment of active sjogren's syndrome | Sjogren syndrome | experimental group :Iguratimod 25mg bid po;control group:hydroxychloroquine 0.2-0.4g/d+prednison0.2-0.5mg/kg.d; | Shanghai Tongji Hospital | Not Recruiting | 18 | 70 | Both | experimental group :60;control group:60; | Phase 4 | China | |
| 12 | NCT03926286 | April 15, 2019 | 14 October 2019 | Fecal Microbial Transplant (FMT) for Sjogrens Syndrome | Fecal Microbial Transplant for Sjogrens Syndrome | Sjogren's Syndrome | Drug: FMP-30 | University of Miami | Sjogrens Syndrome Foundation;Microbiome Health Research Institute | Not recruiting | 18 Years | N/A | All | 10 | Phase 1 | United States |
| 13 | NCT03816345 | April 4, 2019 | 11 November 2019 | Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer | A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm | Biological: Nivolumab | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 264 | Phase 1 | United States | |
| 14 | ChiCTR1900021345 | 2019-02-12 | 18 February 2019 | Effect of Iguratimod on Primary Sjogren's Syndrome | Observation of Iguratimod's Effect on Primary Sjogren's Syndrome, A randomized, double-blind, placebo-controlled trial | Primary Sjogren's Syndrome | Control group :Hydrochloroquine;Treatment group:Iguratimod; | Tianjin Medical University General Hospital | Recruiting | 18 | 75 | Both | Control group :30;Treatment group:30; | New Treatment Measure Clinical Study | China | |
| 15 | EUCTR2017-001371-24-FR | 08/01/2019 | 28 February 2019 | Intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies | Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies - TINISS | Primary Sjögren's syndrome associated painful sensory neuropathies;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Privigen 100 mg/ml, solution pour perfusion Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous drip use (Noncurrent) | Hôpitaux Universitaires de Strasbourg | Authorised | Female: yes Male: yes | 24 | Phase 3 | France | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03817424 | December 13, 2018 | 30 September 2019 | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | Systemic Lupus Erythematosus;Cutaneous Lupus Erythematosus;Sjogren's Syndrome;Systemic Sclerosis;Polymyositis;Dermatomyositis | Drug: VIB7734;Drug: Placebo | Viela Bio | Recruiting | 18 Years | 75 Years | All | 32 | Phase 1 | United States;Poland;Spain | |
| 17 | EUCTR2017-004929-33-AT | 05/12/2018 | 7 January 2019 | Effect of Ciclosporin eyedrops on symptoms of the eye and visual quality in patients with dry eye syndrome and primary or secondary Sjögren syndrome | Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome | primary or secondary Sjögren Syndrome;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Ikervis Product Name: Ikervis Pharmaceutical Form: Eye drops, emulsion INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Trade Name: Softacort Product Name: Softacort Pharmaceutical Form: Eye drops, solution in single-dose container INN or Proposed INN: HYDROCORTISONE SODIUM PHOSPHATE CAS Number: 6000-74-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 3.35- | KH Hietzing, Department of Ophthalmology | Authorised | Female: yes Male: yes | 20 | Phase 4 | Austria | |||
| 18 | NCT03865888 | October 30, 2018 | 3 June 2019 | Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome | Evaluation of the Effect of Topical Application of Tacrolimus 0.03% (FK506) Eye Drops Versus Cyclosporine 0.05% Eye Drops in Treatment of Dry Eye in Secondary Sjogren Syndrome | Dry Eye;Sjogren Syndrome | Drug: Tacrolimus;Drug: Cyclosporins | Pavly Moawd | Not recruiting | 20 Years | 70 Years | All | 60 | Phase 3 | Egypt | |
| 19 | NCT03627065 | September 24, 2018 | 30 September 2019 | A Study of INCB050465 in Primary Sjögren's Syndrome | An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: Parsaclisib | Incyte Corporation | Recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States | |
| 20 | NCT03436576 | September 12, 2018 | 10 September 2018 | Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye | Comparison of Autologous Serum 20% and Autologous Serum 50% for the Treatment of Severe Dry Eye | Dry Eye;Keratoconjunctivitis Sicca;Sjogren's Syndrome;Corneal Diseases;Conjunctival Diseases;Keratitis;Lacrimal Apparatus Diseases | Drug: Autologous Serum 20%;Drug: Autologous Serum 50% | Pontificia Universidad Catolica de Chile | Hospital Dr. Sótero del Río | Recruiting | 18 Years | N/A | All | 20 | Phase 3 | Chile |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03540823 | April 23, 2018 | 6 May 2019 | Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases | Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases | Systemic Lupus;Sjogren's Syndrome | Biological: Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus) | University of Sao Paulo General Hospital | Not recruiting | 9 Years | N/A | All | 300 | Phase 4 | Brazil | |
| 22 | NCT03319420 | March 29, 2018 | 22 July 2019 | Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome | A Randomized, Double-Masked, Comparative Study Versus Systane Ultra UD, to Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome | Dry Eye Due to Sjögren's Syndrome | Drug: LO2A eye drops;Drug: Systane Ultra UD | Ocuwize LTD | Recruiting | 18 Years | 95 Years | All | 60 | Phase 4 | Israel | |
| 23 | NCT03434106 | February 10, 2018 | 19 February 2018 | Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction | Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction | Meibomian Gland Dysfunction;Sjögren's Syndrome | Drug: liposic;Drug: Tears Naturale Forte | LanZhou University | Recruiting | 45 Years | 60 Years | Female | 60 | N/A | China | |
| 24 | ChiCTR1800014623 | 2018-02-01 | 29 January 2018 | A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome | A prospective study on therapeutic effect of Mesenchymal stem cell on patients with primary Sjogren Syndrome | Sjogren Syndrome | stem cell group: Intravenous use mesenchymal stem cell ;hydroxychloroquine group:oral use hydroxychloroquine ; | Tongji Hospital of Tongji University | Recruiting | Both | stem cell group:20;hydroxychloroquine group:20; | New Treatment Measure Clinical Study | China | |||
| 25 | NCT03430388 | January 31, 2018 | 6 May 2019 | Yellow Fever Vaccine in Patients With Rheumatic Diseases | Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area | Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis | Biological: Yellow Fever vaccine (17D) | University of Sao Paulo General Hospital | Not recruiting | 2 Years | 60 Years | All | 600 | N/A | Brazil | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | ChiCTR-IPR-17013772 | 2018-01-01 | 11 December 2017 | A Clinical Multi-center Study of Safety and Efficacy of Tacrolimus Eye Drops in Sjogren's Syndrome Dry Eye | A Clinical Multi-center Study of Safety and Efficacy of Tacrolimus Eye Drops in Sjogren's Syndrome Dry Eye | Sjogren's Syndrome Dry Eye | group of tacrolimus eye drops:tacrolimus eye drops;group of flurometholone eye drops:flurometholone eye drops; | The Eye Hospital of Wenzhou Medical University | Not Recruiting | Both | group of tacrolimus eye drops:30;group of flurometholone eye drops:30; | Post-market | China | |||
| 27 | NCT03840538 | January 1, 2018 | 25 February 2019 | Probiotics as a Prophylaxis to Prevent Clinical Manifestations of Oral Candidosis in Patients With Sjogren's Syndrome | Probiotics as a Prophylaxis to Prevent Clinical Manifestations of Oral Candidosis in Patients With Sjogren's Syndrome | Sjogren's Syndrome | Drug: Probiotic Product - Cap | Cairo University | Not recruiting | 30 Years | 70 Years | All | 32 | Phase 1/Phase 2 | Egypt | |
| 28 | NCT03239600 | September 19, 2017 | 11 June 2018 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) | A Two Part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-a Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren's Syndrome | Autoimmune Diseases | Drug: GSK2618960 2 mg/kg;Drug: Placebo;Drug: Methotrexate | GlaxoSmithKline | Not recruiting | 18 Years | 70 Years | All | 0 | Phase 2 | United Kingdom | |
| 29 | NCT03226444 | June 30, 2017 | 11 November 2019 | Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome | A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome | Primary Sjögren Syndrome;Dry Eye | Drug: 0.005% Lacripep;Drug: 0.01% Lacripep;Drug: Placebo | TearSolutions, Inc. | Not recruiting | 18 Years | N/A | All | 201 | Phase 1/Phase 2 | United States | |
| 30 | EUCTR2016-003292-22-FR | 09/06/2017 | 28 February 2019 | Study of safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome (pSS) | A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome | Primary Sjogren’s syndrome MedDRA version: 19.1 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: VAY736 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Not established CAS Number: Not establis Current Sponsor code: VAY736 Other descriptive name: VAY736 antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 180 | Phase 2 | Portugal;United States;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Argentina;Japan;Germany;Netherlands;Romania;Belgium;Poland | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2016-003292-22-DE | 06/06/2017 | 23 July 2018 | Study of safety and efficacy of ianalumab in patients with primary Sjogren’s Syndrome (pSS) | A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to severe primary Sjogren’s Syndrome | Primary Sjogren’s syndrome MedDRA version: 20.0 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: ianalumab Product Code: VAY736 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: ianalumab CAS Number: Not establis Current Sponsor code: VAY736 Other descriptive name: VAY736 antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 180 | Phase 2 | Portugal;United States;Taiwan;Spain;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Argentina;Poland;Belgium;Romania;Netherlands;Germany;Japan | |||
| 32 | NCT03060005 | May 1, 2017 | 16 December 2017 | Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ? | Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ? | Sjögren's Syndrome;Meibomian Gland Dysfunction | Drug: Tears Naturale Forte;Drug: liposic | Tung Wah Hospital | Recruiting | 50 Years | 60 Years | Female | 80 | N/A | China | |
| 33 | NCT03100942 | May 1, 2017 | 22 October 2019 | Safety and Efficacy Study of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome | Sjogren's Syndrome | Drug: Tirabrutinib placebo;Drug: Lanraplenib placebo;Drug: Filgotinib placebo;Drug: Tirabrutinib;Drug: Lanraplenib;Drug: Filgotinib | Gilead Sciences | Galapagos NV | Not recruiting | 18 Years | 75 Years | All | 152 | Phase 2 | United States;Poland;Spain;United Kingdom |
| 34 | ChiCTR-INR-16009629 | 2017-04-01 | 22 May 2017 | A double blinded Stratified sampling study of Jiedu Tongluo Shengjin prescription in treatment of primary Sjogren syndrome | A double blinded Stratified sampling study of Jiedu Tongluo Shengjin prescription in treatment of primary Sjogren syndrome | primary Sjogren's Syndrome | low disease activity-experimental group:Jiedu Tongluo Shengjin prescription;low disease activity-control group:Jiedu Tongluo Shengjin prescription placebo;moderate disease activity-experimental group:Jiedu Tongluo Shengjin prescription;moderate disease activity-experimental group:prednisone 10mg/d;moderate disease activity-experimental group:Hydorxychloroquine 0.2g/d;moderate disease activity-control group:Jiedu Tongluo Shengjin prescription placebo;moderate disease activity-control group:prednisone 10mg/d;moderate disease activity-control group:Hydorxychloroquine 0.2g/d; | Yueyang Hospital of Integrated Medicine affiliated to Shanghai University of Tradition Chinese Medicine | Not Recruiting | 18 | 70 | Both | low disease activity-experimental group:27;low disease activity-control group:27;moderate disease activity-experimental group:27;moderate disease activity-experimental group:27;moderate disease activity-experimental group:27;moderate disease activity-con | New Treatment Measure Clinical Study | China | |
| 35 | EUCTR2016-004258-14-GB | 21/02/2017 | 8 May 2017 | A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-a Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren’s Syndrome. | A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-a Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren’s Syndrome. - GSK2618960, PH2a, 2-part, repeat IV dose, Immunogenecity, Safety and PK/PD Study in pSS pts | Primary Sjögren’s Syndrome MedDRA version: 19.0 Level: LLT Classification code 10021295 Term: IL-7 therapy System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: GSK2618960 Product Code: GSK2618960 Pharmaceutical Form: Solution for injection INN or Proposed INN: GSK2618960 CAS Number: N/A Current Sponsor code: GSK2618960 Other descriptive name: GSK2618960 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | GlaxoSmithKline Research & Development Limited | Authorised | Female: yes Male: yes | 22 | Phase 2 | United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT03608761 | February 6, 2017 | 18 December 2018 | Comparison Between Rebamipide 2% Versus Autologous Serum | Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study | Dry Eye Syndromes;Sjögren Syndrome | Drug: Rebamipide;Biological: autologous serum;Other: autologous serum and rebamipide 2% | Hospital Nacional Profesor Alejandro Posadas | Not recruiting | 18 Years | N/A | Female | 21 | Phase 4 | Argentina | |
| 37 | JPRN-JapicCTI-173521 | 01/2/2017 | 16 July 2019 | A Phase 3 study of Abatacept in Patients with Primary Sjogrens Syndrome | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjogrens Syndrome | Primary Sjogrens Syndrome | Intervention name : Abatacept INN of the intervention : Abatacept Dosage And administration of the intervention : Abatacept 125 mg subcutaneous injection once per week Control intervention name : Abatacept Placebo Dosage And administration of the control intervention : Placebo for Abatacept subcutaneous injection once per week | Bristol-Myers Squibb K.K. | Not Recruiting | 18 | BOTH | 172 | Phase 3 | |||
| 38 | NCT03247686 | February 1, 2017 | 30 September 2019 | A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome | A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome | Sjogren's Syndrome | Drug: RSLV-132;Drug: Placebo | Resolve Therapeutics | University Hospital Birmingham;Newcastle-upon-Tyne Hospitals NHS Trust | Not recruiting | 18 Years | 70 Years | All | 28 | Phase 2 | United Kingdom |
| 39 | NCT03023592 | February 2017 | 16 December 2017 | Study of Iguratimod in Sjögren's Syndrome | A Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's Syndrome | Sjogren's Syndrome | Drug: Iguratimod | Peking Union Medical College Hospital | Recruiting | 18 Years | 75 Years | All | 30 | Phase 1/Phase 2 | China | |
| 40 | NCT02915159 | December 6, 2016 | 10 December 2018 | A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome | Sjogrens Disease | Other: Placebo;Biological: Abatacept | Bristol-Myers Squibb | Not recruiting | 18 Years | N/A | All | 253 | Phase 3 | United States;Argentina;Australia;Brazil;Czechia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Puerto Rico;Sweden;Canada;Czech Republic | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02503163 | November 23, 2016 | 16 December 2017 | A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome | Dry Eye With Sjögren's Syndrome | Drug: KCT-0809 ophthalmic solution | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | All | Phase 3 | Japan | |||
| 42 | NCT02503189 | November 23, 2016 | 16 December 2017 | A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome | Dry Eye With Sjögren's Syndrome | Drug: KCT-0809 ophthalmic solution;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | All | Phase 3 | Japan | |||
| 43 | NCT02899377 | November 18, 2016 | 4 November 2019 | A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts | A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome | Autoimmune Diseases | Radiation: 18F-FDG PET/CT Imaging;Radiation: 11C-MET PET/CT Imaging;Procedure: MRI Imaging with intravenous contrast with gadoterate meglumine;Procedure: Minor Salivary gland (labial) biopsy | GlaxoSmithKline | Quintiles, Inc. | Not recruiting | 30 Years | N/A | All | 25 | N/A | United Kingdom |
| 44 | NCT02843659 | October 18, 2016 | 9 October 2018 | Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome | A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome | Sjögren's Syndrome | Drug: BMS-931699;Drug: BMS-986142;Drug: Placebo | Bristol-Myers Squibb | Not recruiting | 18 Years | 70 Years | All | 45 | Phase 2 | United States;Australia;Chile;Colombia;Italy;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;France;Hungary | |
| 45 | EUCTR2016-001586-87-GB | 29/09/2016 | 28 February 2019 | A Phase 2 Study of RSLV-132 in Subjects with Sjogren’s Syndrome | A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome - RSLV-132 in Primary Sjogren’s Syndrome | Primary Sjogrens Syndrome;Therapeutic area: Body processes [G] - Immune system processes [G12] | Product Name: RSLV-132 Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Resolve Therapeutics, LLC | Not Recruiting | Female: yes Male: yes | 28 | Phase 2 | United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT02701985 | July 5, 2016 | 16 December 2017 | A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome | Sjogren's Syndrome | Drug: RO5459072;Drug: Placebo | Hoffmann-La Roche | Not recruiting | 18 Years | 75 Years | All | 75 | Phase 2 | United States;France;Germany;Poland;Portugal;United Kingdom | |
| 47 | NCT03762824 | June 14, 2016 | 18 December 2018 | Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease | Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. | Rheumatoid Arthritis;Systemic Lupus;Sjögren Syndrome;Systemic Vasculitis;Spondyloarthritis | Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: 13-valent pneumococcal conjugate vaccine | Region Skane | Not recruiting | 18 Years | N/A | All | 300 | Phase 4 | ||
| 48 | NCT02775916 | June 1, 2016 | 11 June 2018 | Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: CDZ173;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 30 | Phase 2 | Germany;Hungary | |
| 49 | EUCTR2014-004616-12-DE | 20/05/2016 | 19 March 2018 | Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173 | A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome | Primary Sjögren's syndrome MedDRA version: 19.0 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CDZ173 Pharmaceutical Form: Capsule, hard INN or Proposed INN: leniolisib Other descriptive name: CDZ173 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Hungary;Poland;Germany | |||
| 50 | NCT04111341 | May 6, 2016 | 14 October 2019 | A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome. | A Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome. | Sjögren's Syndrome | Drug: TCM (Gan-Lu-Yin)GLY;Drug: PLACEBO | Chung Shan Medical University | Not recruiting | 20 Years | 80 Years | All | 30 | Phase 2 | Taiwan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT03411850 | May 2016 | 29 January 2018 | Sjogrens Syndrome Measured by Ultrasound | Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study | Sjogren's Syndrome | Biological: Orencia;Other: Placebo | Arthritis & Rheumatism Associates, P.C. | Bristol-Myers Squibb | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | United States |
| 52 | NCT02631538 | February 17, 2016 | 7 October 2019 | Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome | A Randomized, Double Blind (Sponsor Open), Comparative, Multicenter Study to Evaluate the Safety and Efficacy of Subcutaneous Belimumab (GSK1550188) and Intravenous Rituximab Co-administration in Subjects With Primary Sjögren's Syndrome | Sjogren's Syndrome | Drug: Belimumab;Drug: Rituximab;Drug: Placebo belimumab;Drug: Placebo rituximab | GlaxoSmithKline | Not recruiting | 18 Years | N/A | All | 79 | Phase 2 | Argentina;Canada;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom | |
| 53 | NCT02691949 | February 2016 | 3 October 2016 | Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome | Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome | Sjogren's Syndrome | Drug: Mycophenolate mofetil | Kaohsiung Medical University | Recruiting | 20 Years | 75 Years | Both | 54 | Phase 2 | ||
| 54 | ChiCTR-OIB-16007789 | 2016-01-18 | 18 April 2017 | 0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation | 0.1%Tacrolimus (FK506) in the treatment of sjogren's syndrome clinical efficacy evaluation | Sjogren's syndrome | Tacrolimus therapy group:0.1% FK506 + 0.1% sodium hyaluronate eye drops Twice a day for 30 days; | Eye Institute of Xiamen University | Recruiting | 18 | 70 | Both | Tacrolimus therapy group:30; | Phase 4 study | China | |
| 55 | EUCTR2015-000400-26-SE | 15/12/2015 | 28 February 2019 | A Phase 2, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of belimumab and rituximab co-administration in subjects with primary Sjögren’s syndrome | A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjögren’s syndrome. | Primary Sjogrens disease MedDRA version: 20.0 Level: PT Classification code 10061664 Term: Autoimmune disorder System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: MabThera (Rituximab) Product Name: MabThera (Rituximab) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Other descriptive name: MABTHERA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Benlysta (Belimumab) Product Name: Benlysta (Belimumab) CAS Number: 356547-88-1 Current Sponsor code: GSK1550188 Other descriptive name: HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | GlaxoSmithKline R&D Ltd | Authorised | Female: yes Male: yes | 120 | Phase 2 | France;Canada;Argentina;Spain;Norway;Netherlands;Germany;United Kingdom;Italy;Sweden | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT02614716 | December 10, 2015 | 18 December 2018 | A Study of LY3090106 in Participants With Sjögren's Syndrome (SS) | A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome | Sjögren's Syndrome | Drug: LY3090106;Drug: Placebo | Eli Lilly and Company | Not recruiting | 18 Years | 65 Years | All | 32 | Phase 1 | United States;Bulgaria;Georgia;Romania | |
| 57 | NCT02495129 | December 2015 | 16 December 2017 | Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome | A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT | Primary Sjögren's Syndrome | Drug: VAY736 lower dose;Drug: VAY736 higher dose | Novartis Pharmaceuticals | Not recruiting | N/A | N/A | All | 0 | Phase 1/Phase 2 | Netherlands | |
| 58 | NCT02610543 | October 2015 | 30 September 2019 | UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: UCB5857;Drug: Placebo | UCB Celltech | PRA Health Sciences | Not recruiting | 18 Years | 75 Years | All | 27 | Phase 2 | France;Italy;Spain;Sweden;United Kingdom;Greece |
| 59 | EUCTR2014-003140-12-NL | 21/09/2015 | 6 October 2015 | Leflunomide and Hydroxychloroquine combination therapy for primary Sjogren's Syndrome | Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - LEF-HCQ combination therapy in pSS | Sjogren's Syndrome MedDRA version: 18.0 Level: LLT Classification code 10040766 Term: Sjogren's disease System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0 Level: LLT Classification code 10042846 Term: Syndrome Sjogren's System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 18.0 Level: LLT Classification code 10040765 Term: Sjogren's System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Leflunomide Mylan Product Name: Leflunomide mylan Pharmaceutical Form: Capsule INN or Proposed INN: LEFLUNOMIDE CAS Number: 75706-12-6 Concentration unit: Bq/mg becquerel(s)/milligram Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plaquenil Product Name: Plaquenil Pharmaceutical Form: Capsule INN or Proposed INN: HYDROXYCHLOROQUINE CAS Number: 118-42-3 Concentration unit: Bq/mg becquerel(s)/milligram Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | UMC Utrecht | Authorised | Female: yes Male: no | Netherlands | |||||
| 60 | JPRN-UMIN000018376 | 2015/07/22 | 23 April 2019 | Efficacy and safety of rituximab for patients with severe rheumatic disease | Efficacy and safety of rituximab for patients with severe rheumatic disease - Efficacy and safety of rituximab for patients with severe rheumatic disease | Childhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome) | 1) Induction Therapy rituximab 375mg/m2 (max500mg) 1-4 times/1-2 weeks 2) Maintenance Therapy rituximab 375mg/m2 (max500mg) 1 times/6-12 months | Yokohama City University Hospital Department of Pediatrics | Not Recruiting | 2years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02334306 | June 8, 2015 | 17 September 2018 | A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome | A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Biological: AMG 557/MEDI5872;Other: Placebo | MedImmune LLC | Amgen | Not recruiting | 18 Years | 75 Years | All | 32 | Phase 2 | United States;France;Sweden;United Kingdom |
| 62 | NCT02503176 | June 2, 2015 | 11 June 2018 | An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome | Dry Eye With Sjögren's Syndrome | Drug: KCT-0809 ophthalmic solution | Kissei Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | All | Phase 3 | Japan | |||
| 63 | NCT02464319 | June 1, 2015 | 11 June 2018 | A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome | Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: hrIL-2 active;Drug: hrIL-2 placebo | Peking University People's Hospital | Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd. | Not recruiting | 18 Years | 65 Years | All | 60 | Phase 2 | China |
| 64 | EUCTR2014-004523-51-GB | 18/05/2015 | 10 September 2018 | UCB Proof of Concept Study in patients with Primary Sjogren’s Syndrome | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN’S SYNDROME | Primary Sjogren’s Syndrome MedDRA version: 19.1 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: UCB5857 Product Code: UCB5857 Pharmaceutical Form: Capsule INN or Proposed INN: UCB5857 CAS Number: 1362850-20-1 Current Sponsor code: UCB5857 Other descriptive name: UCB5857 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: UCB5857 Product Code: UCB5857 Pharmaceutical Form: Capsule INN or Proposed INN: UCB5857 CAS Number: 1362850-20-1 Current Sponsor code: UCB5857 Other descriptive name: UCB5857 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: UCB5857 Product Code: UCB5857 Pharmaceutical Form: Capsule INN or Proposed INN: UCB5857 CAS Number: 1362850-20-1 Current Sponsor code: UCB5857 Other descriptive name: UCB5857 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | UCB Celltech, UK | Not Recruiting | Female: yes Male: yes | 58 | Phase 2 | France;Greece;Spain;Italy;United Kingdom;Sweden | |||
| 65 | EUCTR2014-003896-41-GB | 27/03/2015 | 28 February 2019 | MedImmune Sjogren's Syndrome Study | A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome | Primary Sjogren’s Syndrome MedDRA version: 18.1 Level: LLT Classification code 10042846 Term: Syndrome Sjogren's System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: AMG 557/MEDI5872 Product Code: AMG 557/MEDI5872 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMG 557/MEDI5872 Current Sponsor code: AMG 557/MEDI5872 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | MedImmune, LLC | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | France;United States;United Kingdom;Sweden | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT02633332 | February 2015 | 28 December 2015 | Use of Well Known Drugs for New Destination - RA Improvement (RANT) | Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments | Rheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid Nodules | Drug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanercept | Università Popolare Homo & Natura | Not recruiting | 18 Years | 75 Years | Both | 15 | Phase 1 | Italy | |
| 67 | NCT02257957 | November 2014 | 19 February 2015 | Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye | Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye | Dry Eye;Sjogren Syndrome | Drug: PRP injection;Drug: Standard care Hyaluronic acid eye drops | Universidad Nacional de Colombia | Not recruiting | 18 Years | N/A | Both | 30 | Phase 3 | ||
| 68 | NCT02291029 | October 22, 2014 | 26 August 2019 | Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: CFZ533 active - Cohort 1;Drug: CFZ533 placebo- Cohort 1;Drug: CFZ533 active - Cohort 2;Drug: CFZ533 placebo - Cohort 2;Drug: CFZ533 active -Cohort 3;Drug: CFZ533 active - Cohort 3 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 69 | Phase 2 | United States;Germany;Hungary;Switzerland;United Kingdom | |
| 69 | NCT02067910 | August 2014 | 9 September 2019 | Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome | Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAP III Study = Abatacept Sjögren Active Patients Phase III Study) | Sjögren's Syndrome | Drug: Abatacept SC | University Medical Center Groningen | Bristol-Myers Squibb | Not recruiting | 18 Years | N/A | All | 80 | Phase 3 | Netherlands |
| 70 | EUCTR2013-004808-19-GB | 23/07/2014 | 28 February 2019 | Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CFZ533 | A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjögren’s syndrome - Safety, pharmacokinetics and preliminary efficacy study of CFZ533 in patients with primary Sjögren's | primary Sjögren’s syndrome MedDRA version: 20.0 Level: PT Classification code 10040767 Term: Sjogren's syndrome System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CFZ533 Pharmaceutical Form: Solution for injection INN or Proposed INN: Not yet established Current Sponsor code: CFZ533 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 66 | Phase 2 | United States;Hungary;Germany;Switzerland;United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT02112019 | June 2014 | 16 December 2017 | Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome | Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome; A Randomised Controlled Pilot Study | Sjögren's Syndrome | Procedure: Sialoendoscopy;Drug: saline;Drug: hydrocortisone | Derk Jan Jager | Not recruiting | 18 Years | 70 Years | All | 50 | N/A | Netherlands | |
| 72 | NCT02149420 | May 23, 2014 | 9 October 2018 | PD of VAY736 in Patients With Primary Sjögren's Syndrome | A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: VAY736;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 27 | Phase 2 | Germany;France;Netherlands;United States | |
| 73 | JPRN-UMIN000013234 | 2014/04/01 | 2 April 2019 | Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome | Dry eye related to chronic GVHD and Sjogren s syndrome | Diquafosol sodium and rebamipide ophthalmic solution Artifical tears, vitamin A ophthalmic solution, or/and sodium hyaluronate ophthalmic solution | Keio University School of Medicine | Not Recruiting | 20years-old | 75years-old | Male and Female | 20 | Not applicable | Japan | ||
| 74 | NCT02110446 | February 2014 | 8 February 2016 | Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome | Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome - A Randomized Control Trial | Sjögren's Syndrome | Drug: SS-1;Drug: Placebo | Chang Gung Memorial Hospital | Chang Gung University;National Science Council, Taiwan;China Medical University, China;China Medical University Hospital | Recruiting | 20 Years | 75 Years | Both | 60 | Phase 2 | Taiwan |
| 75 | NCT02855658 | February 2014 | 15 August 2016 | Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome | Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome | Sjögren's Syndrome | Drug: SS-1;Drug: Placebo | China Medical University Hospital | Chang Gung Memorial Hospital;China Medical University, China;National Research Program for Biopharmaceuticals (NRPB) | Recruiting | 20 Years | 75 Years | Both | 90 | Phase 2 | Taiwan |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT01716312 | January 8, 2014 | 11 November 2019 | Omalizumab for Lupus | A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS) | Systemic Lupus Erthematosus;Sjogren's Syndrome | Drug: Omalizumab | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 18 Years | 100 Years | All | 17 | Phase 1 | United States | |
| 77 | ChiCTR-IPR-14005441 | 2014-01-01 | 18 April 2017 | A double blind randomized study of Jiedu Tongluo Shengjin Decoction in treatment of primary Sjogren syndrome | A double blind randomized study of Jiedu Tongluo Shengjin Decoction in treatment of primary Sjogren syndrome | primary Sjogren syndrome | treatment group:hydroxychloroquine+Jiedu Tongluo Shengjin Decoction; | Yueyang Hospital of Integrative Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine | Recruiting | 18 | 65 | Both | treatment group:30; | Phase 1 study | ||
| 78 | NCT02027298 | November 2013 | 16 December 2017 | Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Primary Sjogren's Syndrome;Secondary Sjogren's Syndrome;Inflammatory Arthritis;Rheumatoid Arthritis | Drug: Abatacept | The Cleveland Clinic | Bristol-Myers Squibb | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 79 | NCT01782235 | July 24, 2013 | 2 September 2019 | Efficacy of Tocilizumab in Primary Sjögren's Syndrome. | A Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy of Tocilizumab for the Treatment of Primary Sjögren's Syndrome. | Primary Sjögren's Syndrome (pSS) | Drug: Tocilizumab;Drug: Placebo | University Hospital, Strasbourg, France | Not recruiting | 18 Years | 80 Years | All | 110 | Phase 2/Phase 3 | France | |
| 80 | JPRN-UMIN000010796 | 2013/06/01 | 2 April 2019 | Impact of CYP2A6 and CHRM3 genetic polymorphisms on the PK/PD of pilocarpine in Japanese healthy volunteers | Sjogren's syndrome | single oral administration of pilocarpine. salagen (KISSEI PHARMACEUTICAL CO.,LTD.) 5mg 1Tablet. | Oita University Faculty of Medicine | Not Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | JPRN-UMIN000010710 | 2013/05/15 | 2 April 2019 | Effective treatment of rebamipide on xerostomia in Sjogrens syndrome patients:a pilot study -a double-blind placebo-controlled trial- | Xerostomia in Sjogrens syndrome | Rebamipide was administered orally at 100 mg each time three times a day after meals for 8 weeks. Placebo was administered orally three times a day after meals for 8 weeks. | Tochigi medical center | Not Recruiting | 20years-old | 80years-old | Male and Female | 60 | Phase 2 | Japan | ||
| 82 | JPRN-UMIN000004237 | 2013/03/31 | 2 April 2019 | Efficacy and safety of mizoribine for patients with Sjogren's syndrome in pediatric age | Sjogren's syndrome in pediatric age | Mizoribine 10 mg/kg (up to 500 mg) will be administered once daily twice a week. | Graduate School of Medicine, Chiba University | Not Recruiting | 10years-old | 20years-old | Male and Female | 5 | Phase 2 | Japan | ||
| 83 | NCT02147509 | March 2013 | 19 February 2015 | Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome | Evaluation of the Therapeutic Effect of Bandage Contact Lenses on Dry Eye Caused by Sjogren's Syndrome | Sjögren's Syndrome Patients With Severe Dry Eye | Drug: 0.02% Fm, SH;Drug: 0.02% Fm, SH, 0.05% CsA;Other: 0.02% Fm, SH, tBCL;Drug: 0.02% Fm, SH, AS | Jinyang Li | Not recruiting | 18 Years | 70 Years | Both | 64 | N/A | China | |
| 84 | NCT03578900 | January 1, 2013 | 16 July 2018 | Quality of Life and Sjögren Syndrome | Quality of Life in a Portuguese Population With Primary Sjögren Syndrome | Xerostomia;Hyposalivation;Quality of Life;Sjogren's Syndrome | Drug: Xeros;Drug: Citric Acid based Mouthwash | Grupo de Investigação em Bioquímica e Biologia Oral | University of Lisbon;Portuguese Institute of Rheumatology;Dentaid | Not recruiting | 18 Years | N/A | All | 289 | Phase 4 | |
| 85 | NCT02004067 | January 2013 | 16 December 2017 | Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease | Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease | Primary Sjogren Syndrome;Secondary Sjogren Syndrome;Aqueous Deficient Dry Eye Disease;Evaporative Dry Eye Disease | Drug: Restasis;Drug: Refresh Endura | Federal University of São Paulo | Allergan | Not recruiting | 18 Years | 65 Years | All | 100 | Phase 4 | Brazil |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | NCT01759108 | December 2012 | 19 February 2015 | Rebamipide for the Treatment of Xerostomia in sjögren Syndrome | Improving Symptoms of Dry Mouth in Sjogren's Syndrome | Drug: Rebamipide | Faculty of Medicine, University of Alexandria | Recruiting | N/A | N/A | Both | 55 | N/A | Egypt | ||
| 87 | NCT01552681 | July 2012 | 19 October 2017 | Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome | A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02) | Primary Sjögren's Syndrome | Biological: Baminercept;Other: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence;Biogen | Not recruiting | 18 Years | 75 Years | All | 52 | Phase 2 | United States |
| 88 | EUCTR2011-006196-19-DK | 28/02/2012 | 19 December 2016 | Clinical Trials with lozenge as local anaesthesia as treatment for oral pain of patients with burning mouth syndrome and Sjögrens syndrom | Clinical Trials with lozenge as local anaesthesia as treatment of oral pain in burning mouth syndrome and Sjögrens syndrome - SB Lozenge | Oral pain caused by the illnesses burning mouth syndrome, Sjögren's syndrome and lichen planus;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | Product Name: Bupizenge Product Code: BUPI5 Pharmaceutical Form: Lozenge INN or Proposed INN: BUPIVACAINE HYDROCHLORIDE CAS Number: 18010-40-7 Concentration unit: IU/mg international unit(s)/milligram Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Lozenge Route of administration of the placebo: Oropharyngeal use | Clinical Research Centre, Hvidovre University Hospital | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Denmark | |||
| 89 | NCT01601028 | July 2011 | 19 February 2015 | Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome | Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome | Autoimmune Diseases;Sjogren's Syndrome;Dry Eye | Drug: Hydroxychloroquine;Drug: Placebo | Seoul National University Hospital | Not recruiting | 19 Years | N/A | Both | 39 | Phase 3 | Korea, Republic of | |
| 90 | NCT01316770 | May 1, 2011 | 12 November 2018 | Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects | A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects | Sjögren's Syndrome;Xerostomia | Drug: Placebo Parotid Irrigation;Drug: Dexamethasone Parotid Irrigation | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | 18 Years | N/A | Female | 14 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT01357447 | May 2011 | 19 February 2015 | Pulmozyme for Sjogren's Associated Cough | A Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated Cough | Sjogren's Syndrome;Cough | Drug: Dornase alfa;Drug: Saline | University of Connecticut Health Center | Not recruiting | 18 Years | N/A | Both | 0 | Phase 1 | United States | |
| 92 | NCT01393132 | March 2011 | 19 October 2017 | Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye | Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye | Dry Eye;Sjogren's Syndrome;Graft vs. Host Disease | Drug: Thymosin Beta 4 eye drops;Drug: Vehicle Control | Michigan Cornea Consultants, PC | Kresge Eye Institute | Not recruiting | 18 Years | 90 Years | All | 9 | Phase 2 | United States |
| 93 | NCT01647737 | March 2011 | 19 October 2017 | Green Tea Lozenges for the Management of Dry Mouth | A Natural Formulation for Patients Diagnosed With Xerostomia | Xerostomia;Sjogren Syndrome;Dry Mouth | Dietary Supplement: MighTeaFlow;Dietary Supplement: Xylitol | Augusta University | GlaxoSmithKline | Not recruiting | 18 Years | 75 Years | All | 60 | Phase 1/Phase 2 | United States |
| 94 | JPRN-UMIN000004477 | 2010/11/01 | 2 April 2019 | Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunk | Systemic/cutaneous lupus erythematosus Sjogren's syndrome | Hydroxychloroquine 200 mg will be administrated once daily. If insufficient, dosage can be escalated to 400 mg twice daily, but not exceed 6.5 mg/kg/day. | Kanazawa University Graduate School of Medical Science | Not Recruiting | 20years-old | 75years-old | Male and Female | 10 | Not applicable | Japan | ||
| 95 | NCT01369589 | November 2010 | 29 April 2019 | An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness | An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome | Xerostomia;Sjogren's Syndrome | Drug: P-552;Drug: Placebo | Parion Sciences | Not recruiting | 18 Years | N/A | All | 24 | Phase 1/Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | EUCTR2009-015558-40-NL | 28/07/2010 | 19 March 2012 | Abatacept treatment in patients with primary Sjögren’s syndrome | Abatacept treatment in patients with primary Sjögren’s syndrome | Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry mouth and dry eyes. Extraglandular involvement can occur in SS, and includes, amongst others, pulmonary disease, renal disease and vasculitis. Moreover, almost all patients suffer from restricting fatigue. MedDRA version: 12.0 Level: LLT Classification code 10040767 Term: Sjogren's syndrome | Trade Name: Orencia Pharmaceutical Form: Powder for concentrate for solution for infusion | University Medical Center Groningen | Authorised | Female: yes Male: yes | 15 | Netherlands | ||||
| 97 | NCT01151644 | April 2010 | 19 February 2015 | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Rheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DM | Biological: Anti-pandemic H1N1 influenza vaccine | University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo | Not recruiting | N/A | N/A | Both | 5000 | Phase 4 | Brazil |
| 98 | NCT01081184 | March 2010 | 19 February 2015 | Neurotrophins Implications in Primary Sjögren Syndrome | Neurotrophins Implications in Primary Sjögren Syndrome | Primary Sjögren Syndrome | Biological: blood sample | University Hospital, Limoges | Not recruiting | 18 Years | N/A | Both | 40 | N/A | France | |
| 99 | NCT01160666 | March 2010 | 19 February 2015 | Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome | A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS (BAFF) Antibody, in Subjects With Primary Sjögren's Syndrome | Sjögren's Syndrome | Drug: Belimumab | Assistance Publique - Hôpitaux de Paris | Human Genome Sciences Inc. | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | France |
| 100 | NCT01693393 | March 2010 | 10 August 2015 | Low Dose Cyclosporin A in Primary Sjögren Syndrome | A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome | Sjögren´s Syndrome | Drug: Cyclosporine A | Charite University, Berlin, Germany | Not recruiting | 18 Years | 75 Years | Both | 30 | Phase 2 | Germany | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT01850979 | February 2010 | 19 February 2015 | Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops | Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study | Sjogren Syndrome;Dry Eye Syndrome | Drug: Tacrolimus;Drug: Olive Oil | University of Sao Paulo General Hospital | Not recruiting | 40 Years | 60 Years | Both | 24 | Phase 4 | Brazil | |
| 102 | EUCTR2009-015978-35-FR | 30/11/2009 | 19 March 2012 | Etude ouverte de phase 2 de 52 semaines visant à établir l'efficacité et la tolérance du Belimumab (HGS1006, LymphoStat-B), un anticorps monoclonal humanisé anti-BLys (BAFF), chez des patients atteints de syndrome de Sjögren primitif - BELISS | Etude ouverte de phase 2 de 52 semaines visant à établir l'efficacité et la tolérance du Belimumab (HGS1006, LymphoStat-B), un anticorps monoclonal humanisé anti-BLys (BAFF), chez des patients atteints de syndrome de Sjögren primitif - BELISS | Syndrome Sjogren's MedDRA version: 8.1 Level: PT Classification code 10042846 Term: Syndrome Sjogren's | Product Name: HGS1006, LymphoStat-B Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: belimumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | 30 | Phase 2 | France | |||
| 103 | NCT01008982 | August 2009 | 19 February 2015 | Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome | A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Primary Sjögren's Syndrome. | Sjögren's Syndrome | Drug: LimphoStat-B | University of Udine | Azienda Ospedaliera S. Maria della Misericordia | Not recruiting | 18 Years | 90 Years | Both | 15 | Phase 2 | Italy |
| 104 | NCT00953485 | June 2009 | 19 February 2015 | Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) | Clinical Trial of Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome - Phase ?/? | Sjogren's Syndrome;Mesenchymal Stem Cells | Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | 15 Years | 70 Years | Both | 20 | Phase 1/Phase 2 | China | |
| 105 | JPRN-UMIN000029307 | 2009/02/01 | 2 April 2019 | Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients | Sjogren's syndrome | Pilocarpine / sodium alginate solution (0.32 mL, pilocarpine 0.96 mg) is administered intra-orally 3 times a day for 7 days. | Teikyo University | Not Recruiting | 16years-old | Not applicable | Male and Female | 50 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT00852839 | February 2009 | 24 September 2018 | A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome | A Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome | Dry Mouth Associated With Sjogren's Syndrome;Xerostomia | Drug: Placebo;Drug: 552-02 | Parion Sciences | Not recruiting | 18 Years | 80 Years | All | 140 | Phase 2 | United States | |
| 107 | EUCTR2009-013976-38-DE | 18 April 2012 | Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress | Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress | Primary Sjögren's Syndrome MedDRA version: 12.1 Level: LLT Classification code 10059142 Term: Sjoegren's syndrome | Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral Pharmaceutical Form: Capsule, soft INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral Pharmaceutical Form: Capsule, soft INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral Pharmaceutical Form: Capsule, soft INN or Proposed INN: CICLOSPORIN CAS Number: 59865-13-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Charité Berlin, Department of rheumatology | Charité Berlin, department of rheumatology;Charité Berlin, department of rheumatology | Authorised | Female: yes Male: yes | Phase 2 | Germany | ||||
| 108 | JPRN-UMIN000001460 | 2008/10/01 | 2 April 2019 | The efficacy and safety of pirocarpine hydrochloride for juvenile Sjogren's syndrome | Sjogren's syndrome | Oral pilocarpine hydrochloride for 4 weeks. | Department of Pediatrics, Graduate School of Medicine, Chiba Univerity | Not Recruiting | 6years-old | 16years-old | Male and Female | 10 | Not selected | Japan | ||
| 109 | EUCTR2007-003537-16-NL | 04/09/2008 | 19 March 2012 | Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study | Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study | Primary Sjogren's Syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome | Product Name: estetrol Product Code: E4 Pharmaceutical Form: Oral solution | Erasmus MC | Authorised | Female: yes Male: no | Netherlands | |||||
| 110 | EUCTR2007-001377-28-FR | 11/06/2008 | 19 March 2012 | Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL | Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL | Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously, -- AND who developed adverse events (AEs) corresponding to pre-specified newly diagnosed autoimmune disorders OR who developed severe thrombocytopenia. MedDRA version: 9.1 Level: LLT Classification code 10061664 Term: Autoimmune disorder MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic MedDRA version: 9.1 Level: LLT Classification code 10047888 Term: Wegener's granulomatosis MedDRA version: 9.1 Level: LLT Classification code 10002817 Term: Antiphospholipid syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10009900 Term: Colitis ulcerative MedDRA version: 9.1 Level: LLT Classification code 10003827 Term: Autoimmune hepatitis MedDRA version: 9.1 Level: LLT Classification code 10049046 Term: Autoimmune thyroiditis MedDRA version: 9.1 Level: LLT Classification code 10003822 Term: Autoimmune haemolytic anaemia NOS MedDRA version: 9.1 Level: LLT Classification code 10034697 Term: Pernicious anemia MedDRA version: 9.1 Level: LLT Classification code 10028417 Term: Myasthenia gravis MedDRA version: 9.1 Level: LLT Classification code 10018620 Term: Goodpasture's syndrome MedDRA version: 9.1 Level: LLT Classification code 10 | Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Efalizumab Other descriptive name: EFALIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- | Merck Serono International S.A. | Authorised | Female: yes Male: yes | 92 | Phase 4 | Portugal;Germany;Netherlands;France;Austria | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | NCT00632866 | March 2008 | 19 February 2015 | Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome | Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: Hydroxychloroquine;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Sanofi | Not recruiting | 18 Years | N/A | Both | 120 | Phase 3 | France |
| 112 | NCT00631358 | February 2008 | 19 October 2017 | Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention | Sjogren's Syndrome | Drug: Maxidex;Other: No treatment | Alcon Research | Not recruiting | 17 Years | N/A | All | 97 | Phase 4 | Canada | ||
| 113 | NCT00637793 | February 2008 | 19 February 2015 | Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome | A Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's Syndrome | Xerostomia;Sjogren's Syndrome | Drug: NGX267 | TorreyPines Therapeutics | Not recruiting | 21 Years | 55 Years | Both | 24 | Phase 2 | United States | |
| 114 | JPRN-UMIN000000997 | 2008/01/01 | 2 April 2019 | The non-blind test crossover controlled trial how we used a physically unimpaired person volunteer about quantity of salivary secretion increase action of gargle remedy of cevimeline hydrochloride hydrate | Xerostomia due to Sjogren`s syndrome | It is a gargle with a test drug(Cevimeline hydrochloride hydrate 30mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo1 (Cevimeline hydrochloride hydrate 9mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo2 (Hachiazule(TM)gargle2g+distilled water 50cc)for two minutes. It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes. It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo1 for two minutes. It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes. It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out,It is a gargle with false placebo2 for two minutes. It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes. | Department of Dentistry and Oral Surgery, Tochigi National Hospital | National Institute of Public Health | Not Recruiting | 20years-old | 90years-old | Male and Female | 12 | Phase 1 | Japan | |
| 115 | NCT00438048 | November 2006 | 19 February 2015 | A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment | Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva | Primary Sjogren;Secondary Sjogren;Xerostomia | Procedure: pilocarpine;Drug: Artificial Saliva | Pontificia Universidad Catolica de Chile | Formulario MAgistral Farmacias Ahumada | Not recruiting | 18 Years | N/A | Both | 76 | Phase 4 | Chile |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT00363350 | August 2006 | 19 February 2015 | Rituximab Treatment in Sjogren's Syndrome | Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial | Sjogren's Syndrome | Drug: rituximab (anti-CD20) | University Medical Centre Groningen | Hoffmann-La Roche | Not recruiting | 18 Years | 85 Years | Both | 30 | Phase 1/Phase 2 | Netherlands |
| 117 | NCT00344448 | June 2006 | 19 October 2017 | Pilot Study of Raptiva to Treat Sjogren's Syndrome | A Randomized, Placebo Controlled, Proof of Concept, Study of Raptiva, a Humanized Anti-CD-11a Monoclonal Antibody, in Patients With Sjogren's Syndrome | Sjogren's Syndrome | Drug: Raptiva | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States | |
| 118 | NCT00542763 | April 2005 | 19 February 2015 | Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome | Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome - An Open Label Pilot Trial | Primary Sjogren's Syndrome | Drug: Mycophenolate sodium | University Hospital Muenster | Novartis | Not recruiting | 18 Years | 75 Years | Both | 12 | Phase 1 | Germany |
| 119 | NCT00233363 | March 2005 | 19 February 2015 | Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome | An Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s Syndrome | Xerostomia;Sjogren's Syndrome | Drug: Rebamipide | Otsuka Pharmaceutical Co., Ltd. | Not recruiting | 20 Years | N/A | Both | 100 | Phase 2 | Japan | |
| 120 | NCT00873496 | January 2005 | 19 February 2015 | Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients | Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study. | Sjögren's Syndrome;Xerostomia | Drug: Hydroxychloroquine | Ege University | Not recruiting | N/A | N/A | Female | 30 | N/A | Turkey | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | NCT00101829 | April 2004 | 16 December 2017 | Anti-CD20 Antibody Therapy for Sjogren's Syndrome | An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome | Sjogren's Syndrome | Drug: Rituximab | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Not recruiting | 18 Years | 75 Years | All | 12 | Phase 1 | United States |
| 122 | NCT00278512 | August 2003 | 8 August 2016 | Hematopoietic Stem Cell Support in Vasculitis | High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome | Vasculitis | Biological: Autologous Stem Cell Transplant;Biological: Allogeneic Stem Cell Transplant | Northwestern University | Not recruiting | 16 Years | 60 Years | Both | 7 | Phase 1 | United States | |
| 123 | NCT00543166 | February 2003 | 19 February 2015 | Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue | Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue | Sjogren's Syndrome | Drug: dehydroepiandrosterone | Helsinki University | Göteborg University;Uppsala University | Not recruiting | 18 Years | 80 Years | Both | 107 | Phase 4 | Finland |
| 124 | NCT00025818 | May 2001 | 19 February 2015 | Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome | Keratoconjunctivitis Sicca;Sjogren's Syndrome;Lupus Erythematosus, Systemic;Arthritis, Rheumatoid;Scleroderma, Systemic | Drug: Ophthalmic Emulsion | Allergan | Not recruiting | 18 Years | N/A | Both | 290 | Phase 3 | United States | ||
| 125 | NCT00391924 | May 2000 | 19 February 2015 | Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome | Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration | Lupus Erythematosus, Systemic;Sjogren's Syndrome | Drug: Dehydroepiandrosterone | UMC Utrecht | University Medical Centre Groningen;Dutch Arthritis Association | Not recruiting | 18 Years | N/A | Female | 120 | Phase 2 | Netherlands |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | NCT00001954 | December 1999 | 19 February 2015 | Etanercept Therapy for Sjogren's Syndrome | Etanercept Therapy for Sjogren's Syndrome | Sjogren's Syndrome | Drug: Etanercept | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | N/A | N/A | Both | 28 | Phase 2 | United States | |
| 127 | NCT00001731 | November 1997 | 19 February 2015 | Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops | A Double-Masked, Randomized, Vehicle-Controlled Pilot Study of the Treatment of Keratoconjunctivitis Sicca With Topical Cyclosporin A 0.1% Emulsion | Keratoconjunctivitis Sicca;Sjogren's Syndrome | Drug: Cyclosporin A | National Eye Institute (NEI) | Not recruiting | N/A | N/A | Both | 30 | Phase 2 | United States | |
| 128 | NCT00001598 | May 1997 | 19 February 2015 | DHEA Treatment for Sjogren's Syndrome | Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome | Lacrimal Apparatus Disease;Salivary Gland Disease;Sjogren's Syndrome;Xerostomia | Drug: Dehydroepiandrosterone | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | N/A | N/A | Female | 28 | Phase 2 | United States | |
| 129 | NCT00001599 | May 1997 | 19 February 2015 | Pilot Study of Thalidomide to Treat Sjogren's Syndrome | Pilot Study of Thalidomide for Sjogren's Syndrome | Sjogren's Syndrome;Xerostomia | Drug: Thalidomide | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | N/A | N/A | Female | 28 | Phase 2 | United States | |
| 130 | JPRN-JapicCTI-050036 | 23 April 2019 | Exploratory study of rebamipide to evaluate the efficacy and safety in treatment of dry mouth in patients with Sjogren's syndrome | Exploratory study of rebamipide to evaluate the efficacy and safety in treatment of dry mouth in patients with Sjogren's syndrome | Dry mouth in patients with Sjogren's syndrome | Intervention name : Rebamipide Dosage And administration of the intervention : Oral | Otsuka Pharmaceutical Co., Ltd. | 20 | BOTH | Phase 2 |